Trials / Active Not Recruiting
Active Not RecruitingNCT04736823
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 265 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 | IV infusion |
| DRUG | Pemetrexed | IV infusion |
| DRUG | Paclitaxel | IV infusion |
| DRUG | Carboplatin | IV infusion |
| DRUG | Docetaxel | IV infusion |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2026-07-01
- Completion
- 2026-12-01
- First posted
- 2021-02-03
- Last updated
- 2026-03-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04736823. Inclusion in this directory is not an endorsement.